<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348682</url>
  </required_header>
  <id_info>
    <org_study_id>19-001868</org_study_id>
    <nct_id>NCT04348682</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging</brief_title>
  <official_title>Expanded Access Protocol of 68Ga-PSMA-11 for Prostate Cancer PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      To provide expanded access to 68Ga-PSMA-11 PET imaging for eligible participants to detect&#xD;
      and localize prostate cancer for initial and subsequent treatment strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate-specific membrane antigen (PSMA) targeted Positron Emission Tomography (PET) imaging&#xD;
      has been embraced enthusiastically worldwide. Given the unmet clinical need for accurately&#xD;
      diagnosing and staging prostate cancer and the encouraging results of 68Ga-PSMA-11 PET&#xD;
      worldwide, University of California Los Angeles (UCLA) and University of California San&#xD;
      Francisco (UCSF) conducted pivotal registration trials to assess 68Ga-PSMA-11's safety and&#xD;
      efficacy profile in detecting prostate cancer in adult patients. To gap the unmet clinical&#xD;
      need of 68Ga-PSMA-11 PET during the period prior to FDA approval, UCLA Nuclear Medicine&#xD;
      offers expanded access of this investigational PET drug to eligible participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron Emission Tomography (PET) Imaging</intervention_name>
    <description>A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Biochemical recurrent (i. Inclusion/Exclusion) and preprostatectomy (ii.&#xD;
        Inclusion/Exclusion) staging patients will be eligible for the expanded access protocol. In&#xD;
        order to be eligible to participate in this study, an individual must meet the following&#xD;
        criteria:&#xD;
&#xD;
        Biochemical Recurrence Population:&#xD;
&#xD;
        i. Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological proven prostate adenocarcinoma.&#xD;
&#xD;
          -  Rising prostatic specific antigen(PSA) after definitive therapy with prostatectomy or&#xD;
             radiation therapy.&#xD;
&#xD;
               -  Post radical prostatectomy (RP)&#xD;
&#xD;
               -  PSA equals to or greater than 0.2 ng/mL measured more than 6weeks after RP&#xD;
&#xD;
               -  Post-radiation therapy -ASTRO-Phoenix consensus definition&#xD;
&#xD;
               -  Nadir + greater than or equal to 2 ng/mL rise in PSA&#xD;
&#xD;
          -  Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group (ECOG)/&#xD;
             World Health Organization (WHO) equivalent).&#xD;
&#xD;
          -  Age &gt; 18.&#xD;
&#xD;
          -  Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it.&#xD;
&#xD;
             i. Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant investigational therapy.&#xD;
&#xD;
          -  Known inability to lie flat, remain still or tolerate a PET scan.&#xD;
&#xD;
          -  Patient undergoing active treatment for non-prostate malignancy, other than skin basal&#xD;
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and&#xD;
             superficial bladder cancer.&#xD;
&#xD;
        Preprostatectomy Staging Population:&#xD;
&#xD;
        ii. Inclusion criteria:&#xD;
&#xD;
          -  Biopsy proven prostate adenocarcinoma.&#xD;
&#xD;
          -  Considered for prostatectomy with lymph node dissection.&#xD;
&#xD;
          -  Intermediate to high-risk disease (as determined by elevated PSA [PSA&gt;10], T-stage&#xD;
             [T2b or greater], Gleason score [Gleason score &gt; 6] or other risk factors).&#xD;
&#xD;
          -  Able to provide written consent.&#xD;
&#xD;
          -  Karnofsky performance status of ≥50 (or ECOG/WHO equivalent).&#xD;
&#xD;
        ii. Exclusion criteria:&#xD;
&#xD;
          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability&#xD;
             to lay still for the duration of the exam.&#xD;
&#xD;
          -  Neoadjuvant chemotherapy, radiation therapy or any definitive local therapy prior to&#xD;
             prostatectomy including focal ablation techniques (HiFu).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participation is not based on self-representation. Participation is based on the possession of a prostate gland.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

